Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05544552 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Tyra Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 19
- Study locations
NCT05544552 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is active but no longer recruiting, run by Tyra Biosciences. The registered enrollment target is 310 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (41% higher). The trial reports 19 study locations across 10 states.
The verdict
NCT05544552, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Tyra Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.
Conditions Studied
Interventions
- DRUG TYRA-300
Study Locations (19)
Other
- Institut de Cancerologie de L'Ouest (ICO) - Saint-Herblain
- Institut Claudius Regaud, IUCT-Oncopole - Toulouse
- Gustave Roussy (Institut de Cancerologie Gustave-Roussy) - Villejuif
- NEXT Barcelona - Hospital Quironsalud Barcelona - Barcelona
- Vall d'Hebron Institut d'Oncologia (VHIO) - Barcelona
- NEXT Madrid - Hospital Universitario Quironsalud Madrid - Madrid
Massachusetts
- Dana Farber Cancer Institute - Boston
- UMass Memorial Medical Center - Worchester
Washington
- Seattle Cancer Care Alliance (SCCA) - South Lake Union - Seattle
- Linear Clinical Research Limited - Nedlands
Queensland
- Tasman Oncology - Southport
- Princess Alexandra Hospital - Woolloongabba
Victoria
- Austin Health - Heidelberg
- Peter MacCallum Cancer Research Unit - Melbourne
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
North Carolina
- Duke Cancer Institute (DCI) - Duke Cancer Center - Durham
Ohio
- Cleveland Clinic - Main Campus - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2022-11-22 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05544552
The ClinicalTrials.gov registry entry for NCT05544552 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (41% higher). The listed sponsor is Tyra Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TYRA-300 is the first listed.
NCT05544552 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Other, Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT05544552 about?
NCT05544552 is a clinical study titled "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced s...
What is the current status of trial NCT05544552?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2022-11-22. Estimated completion is 2027-06.
What conditions does trial NCT05544552 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor, Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Adult.
What interventions are being tested in trial NCT05544552?
The interventions under investigation include: TYRA-300 (DRUG).
Who is sponsoring clinical trial NCT05544552?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05544552 being conducted?
This trial has 19 study locations across Massachusetts, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.